Elevated blood pressure, called hypertension, is the leading risk factor for death and disability worldwide.  However, many patients find it is not possible to achieve a healthy blood pressure despite taking three or more blood-pressure-lowering medications; a condition referred to as resistant hypertension.

Professor Markus Schlaich at The University of Western Australia, together with colleagues from other centres worldwide, has conducted the PRECISION clinical trial to assess whether the novel drug aprocitentan could improve blood pressure control in patients with resistant hypertension.

Read the original research: doi.org/10.1007/s11906-023-01259-z

Read more in Research Features